Gemtuzumab Ozogamicin: Time to Resurrect?-Reference-Cited by-同舟云学术

Gemtuzumab Ozogamicin: Time to Resurrect?

Published:2012-11-10 Issue:32 Volume:30 Page:3921-3923
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Ravandi Farhad¹,Estey Elihu H.²,Appelbaum Frederick R.²,Lo-Coco Francesco³,Schiffer Charles A.⁴,Larson Richard A.⁵,Burnett Alan K.⁶,Kantarjian Hagop M.¹

Affiliation:

1. University of Texas MD Anderson Cancer Center, Houston, TX

2. Fred Hutchinson Cancer Research Center, Seattle, WA

3. Tor Vergata University and Santa Lucia Foundation, Rome, Italy

4. Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI

5. University of Chicago Pritzker School of Medicine, Chicago, IL

6. School of Medicine, Cardiff University, Cardiff, United Kingdom

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2012.43.0132

Reference18 articles.

1. Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse

2. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

3. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy

4. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-drug conjugates: Principles and opportunities;Life Sciences;2024-06

2. Chimeric Antigen Receptor Therapy in Acute Myeloid Leukemia;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

3. Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions;Archives of Pharmacal Research;2023-12-28

4. Fever with Thrombocytopenia—Look beyond Infection: A Case Report;Journal of Acute Care;2023-10-30

5. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability;The Oncologist;2023-09-04